Summary

Overview
The U.K. clinical nutrition market reached US$ 940.93 million in 2024 and is expected to reach US$ 1,069.55 million by 2033, growing at a CAGR of 2.4 % during the forecast period 2025-2033.
Clinical nutrition products are pharmaceutical products that help keep a patient healthy. It helps to improve the metabolic system by providing adequate supplements such as minerals, vitamins, and others. Clinical nutrition products are useful in maintaining the patient's health and improving the body's metabolic system by providing adequate supplements, such as minerals, vitamins, and other supplements.
The clinical nutrition market in the UK is a sector dedicated to providing specialized nutritional support and products for patients with specific health needs, particularly those suffering from chronic diseases or malnutrition. This market includes a diverse range of products such as enteral and parenteral nutrition solutions, medical foods, and dietary supplements that are designed to meet the nutritional requirements of individuals in various healthcare settings.
Clinical nutrition can be defined as the field that examines the relationship between diet, nutrition, and health outcomes. It encompasses the prevention, diagnosis, and management of nutritional issues associated with various medical conditions. The primary goal of clinical nutrition is to ensure that patients receive adequate nutrients to support their recovery and overall health, especially in situations where traditional dietary intake is insufficient due to illness or medical treatment. These factors have driven the U.K. clinical nutrition market expansion.
Market Dynamics: Drivers & Restraints
Rise in the Prevalence of Metabolic Disorders
The UK clinical nutrition market is experiencing growth due to factors such as rising metabolic disorders prevalence, high healthcare spending, and the rise of the middle class in emerging economies, indicating a growing market.
The rise in the prevalence of metabolic diseases, such as obesity, hypertension, insulin resistance, and hyperlipidemia, is a significant public health issue worldwide. These disorders are associated with chronic degenerative diseases, such as type 2 diabetes, obesity, and cardiovascular disease. The role of nutrition in metabolic disorders is well investigated, but there is still a growing interest in elucidating the nutrients/foods that execute their actions on human metabolism and metabolic disorders.
For instance, according to the International Diabetes Federation, a total of 60 data sources from 39 countries were used to generate diabetes estimates among adults in the region. According to the data, the diabetes prevalence (9.2%) and number of people with diabetes (61 million) in Europe region will increase 13 % by 2045. Europe region has the highest number of children and adolescents with type 1 diabetes (295,000) as well as the highest incidence annually with 31,000 new cases per year.
Hence, the rise in the number of metabolic disorders and other chronic diseases will increase the demand for clinical nutrition directly which will help the market to grow during the forecast period. Moreover, the increasing focus of consumers on health and wellness contributes to the U.K. clinical nutrition market expansion.
Lack of Awareness for Clinical Nutrition
The demand for clinical nutrition is increasing, but there is a lack of awareness about healthcare and diet in both developed and developing countries. This lack of understanding leads to deficiencies and disorders due to a lack of proper knowledge of vitamins and nutrition, and incorrect information. Education and direct support for health and hygiene are not sufficient. Despite campaigns promoting awareness about clinical nutrition benefits for different diseases, there is still a lack of understanding about clinical nutrition for various illnesses, which is expected to hamper the market.
However, lack of awareness especially in emerging countries, and stringent government regulations are a few of the restraints that may result in lower adoption of alternate means of nutrition. The clinical nutrition market growth can be affected in the least developed regions of the world with comparatively lower standards of living attributed to the refusal of rationalized means to consume nutrition and, lack of acceptance of newer approaches.
There is a widespread lack of understanding among the general public regarding the significance of clinical nutrition in managing health conditions. Many people fail to recognize how nutrition can influence chronic diseases or aid in recovery from illnesses. Thus, the above factors could be limiting the U.K. clinical nutrition market's potential growth.
Segment Analysis
The U.K. clinical nutrition market is segmented based on Product Type, Age Group, route of administration, application, Distribution Channel, and region.
Product Type:
The enteral nutrition segment is expected to dominate the U.K. clinical nutrition market share
The enteral nutrition segment holds a major portion of the U.K. clinical nutrition market share and is expected to continue to hold a significant portion of the U.K. clinical nutrition market share during the forecast period. Enteral nutrition is an essential aspect of healthcare for individuals with a functioning digestive system who are unable to eat or drink. Nestlé Health Science, a leader in the field, offers a wide range of enteral feeding products and solutions designed to support various life stages, from pediatrics to healthy aging.
If the gut is working normally to absorb food and nutrients, then Enteral Nutrition is the preferred way of delivering nutritional support. In some patients, enteral nutrition may have to be delivered into the gut through a tube, but in others, it may be possible for them to take this by mouth. This segment has seen substantial growth due to several factors, such as the rising elderly population, the growing incidence of chronic diseases, and a trend towards care being provided in home settings.
Furthermore, major players in the industry key initiatives and expansion of the industry that would propel this segment growth in the U.K. clinical nutrition market. For instance, in October 2022, Galen Medical Nutrition, a subsidiary of Galen Limited, launched TYR EASY Tablets in the UK, marking the first solid-dose protein substitute option for individuals over 8 years old with tyrosinemia. This provides patients with a greater variety of protein substitutes to better suit their individual needs.
Also, in May 2021, Willows Veterinary Centre expanded its clinical nutrition service by launching a specialist-led parenteral nutrition service. Willows is one of the few specialist centers in Europe with a board-certified specialist in clinical nutrition. This service provides intravenous nutrition, including protein, carbohydrates, and fat solutions, to patients when other feeding methods are not possible. These factors have solidified the segment's position in the U.K. clinical nutrition market.
Competitive Landscape
The major global players in the pollinosis market include Abbott Laboratories (Abbott Nutrition), Nestle Health Science, Baxter International Inc, B. Braun Melsungen AG, Danone (Nutricia), BASF SE, Perrigo Company PLC, DSM-Firmenich AG, AYMES International Ltd, and Nualtra among others.
Key developments
• In January 2023, Nutricia, a Danone-owned company, launched its first plant-based medical nutrition drink, Fortimel PlantBased Energy, to address the nutritional needs of individuals who are malnourished or at risk of malnutrition due to illness. This ready-to-drink oral nutritional supplement is made with high-quality plant protein from pea and soy sources, making it suitable for vegans, vegetarians, flexitarians, and those with cow's milk protein allergies. It is designed to match the nutritional profile of the original dairy formula.
Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
The U.K. clinical nutrition market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2023
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.

• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.

• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.

• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.

• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.

• Supply Chain: Distribution and Supply Chain Managers.

• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.

• Academic & Research: Academic Institutions.

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Age Group
3.3. Snippet by Route of Administration
3.4. Snippet by Application
3.5. Snippet by Distribution Channel
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the Prevalence of Metabolic Disorders
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Lack of Awareness for Clinical Nutrition
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Strategic Insights and Industry Outlook
5.1. Market Leaders and Pioneers
5.1.1. Emerging Pioneers and Prominent Players
5.1.2. Established leaders with largest largest-selling Brand
5.1.3. Market leaders with established Product
5.2. CXO Perspectives
5.3. Latest Developments and Breakthroughs
5.4. Case Studies/Ongoing Research
5.5. Regulatory and Reimbursement Landscape
5.5.1. North America
5.5.2. Europe
5.5.3. Asia Pacific
5.5.4. Latin America
5.5.5. Middle East & Africa
5.6. Porter’s Five Force Analysis
5.7. Supply Chain Analysis
5.8. Patent Analysis
5.9. SWOT Analysis
5.10. Unmet Needs and Gaps
5.11. Recommended Strategies for Market Entry and Expansion
5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
5.13. Pricing Analysis and Price Dynamics
5.14. Key Opinion Leaders
6. By Product Type
6.1. Introduction
6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
6.1.2. Market Attractiveness Index, By Product Type
6.2. Infant Nutrition*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Enteral Nutrition
6.4. Parenteral Nutrition
7. By Age Group
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
7.1.2. Market Attractiveness Index, By Age Group
7.2. Adult*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Pediatric
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Enteral
8.4. Parenteral
9. By Application
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.1.2. Market Attractiveness Index, By Application
9.2. Oncology*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Metabolic Disorders
9.4. Gastrointestinal Disorders
9.5. Neurological Disorders
9.6. Others
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Abbott Laboratories (Abbott Nutrition) *
12.1.1. Company Overview
12.1.2. Product Portfolio
12.1.2.1. Product Description
12.1.2.2. Product Key Performance Indicators (KPIs)
12.1.2.3. Historic and Forecasted Product Sales
12.1.2.4. Product Sales Volume
12.1.3. Financial Overview
12.1.3.1. Company Revenue’s
12.1.3.2. Geographical Revenue Shares
12.1.3.3. Revenue Forecasts
12.1.4. Key Developments
12.1.4.1. Mergers & Acquisitions
12.1.4.2. Key Product Development Activities
12.1.4.3. Regulatory Approvals etc.
12.1.5. SWOT Analysis
12.2. Nestle Health Science
12.3. Baxter International Inc
12.4. B. Braun Melsungen AG
12.5. Danone (Nutricia)
12.6. BASF SE
12.7. Perrigo Company PLC
12.8. DSM-Firmenich AG
12.9. AYMES International Ltd
12.10. Nualtra
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us